{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:15:36Z","timestamp":1780359336859,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T00:00:00Z","timestamp":1507852800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Fujian Provincial Health and Family Planning Commission","award":["2014-ZQN-JC-15"],"award-info":[{"award-number":["2014-ZQN-JC-15"]}]},{"name":"Fujian Provincial Health and Family Planning Commission","award":["2015-CX-R4"],"award-info":[{"award-number":["2015-CX-R4"]}]},{"name":"Fujian Provincial Planning Office of Social Sciences","award":["2014C042"],"award-info":[{"award-number":["2014C042"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1007\/s40261-017-0587-z","type":"journal-article","created":{"date-parts":[[2017,10,13]],"date-time":"2017-10-13T03:12:56Z","timestamp":1507864376000},"page":"79-86","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China"],"prefix":"10.1007","volume":"38","author":[{"given":"Na","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Fu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Feng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Zhu","family":"Weng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Mei","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Bai","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,10,13]]},"reference":[{"issue":"9","key":"587_CR1","doi-asserted-by":"crossref","first-page":"984","DOI":"10.6004\/jnccn.2009.0065","volume":"7","author":"National Comprehensive Cancer Network","year":"2009","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. Natl Compr Canc Netw. 2009;7(9):984\u20131023.","journal-title":"Natl Compr Canc Netw"},{"issue":"8","key":"587_CR2","first-page":"633","volume":"37","author":"Chinese Society of Hematology, Chinese Medical Association","year":"2016","unstructured":"Chinese Society of Hematology, Chinese Medical Association. The guidelines for diagnosis and treatment of chronic myelogenous leukemia in China (2016 edition). Chin J Hematol. 2016;37(8):633\u20139.","journal-title":"Chin J Hematol"},{"issue":"24 Suppl 15","key":"587_CR3","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.2146\/ajhp070482","volume":"64","author":"C Fausel","year":"2007","unstructured":"Fausel C. Targeted chronic myeloid leukemia therapy: seeking a cure. Am J Health Syst Pharm. 2007;64(24 Suppl 15):S9\u201315.","journal-title":"Am J Health Syst Pharm"},{"issue":"9976","key":"587_CR4","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley JF. Chronic myeloid leukaemia. Lancet. 2015;385(9976):1447\u201359.","journal-title":"Lancet"},{"issue":"6","key":"587_CR5","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3109\/0284186X.2010.495132","volume":"49","author":"O Ghatnekar","year":"2010","unstructured":"Ghatnekar O, Hjalte F, Taylor M. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with chronic myeloid leukemia (CML), resistant to standard dose imatinib\u2014a Swedish model application. Acta Oncol. 2010;49(6):851\u20138.","journal-title":"Acta Oncol"},{"issue":"4","key":"587_CR6","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.clinthera.2014.02.008","volume":"36","author":"W Kulpeng","year":"2014","unstructured":"Kulpeng W, Sompitak S, Jootar S, et al. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand. Clin Ther. 2014;36(4):534\u201343.","journal-title":"Clin Ther"},{"issue":"8","key":"587_CR7","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.jval.2011.07.006","volume":"14","author":"M Hoyle","year":"2011","unstructured":"Hoyle M, Rogers G, Moxham T, et al. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or -intolerant chronic phase chronic myeloid leukemia. Value Health. 2011;14(8):1057\u201367.","journal-title":"Value Health"},{"issue":"7","key":"587_CR8","doi-asserted-by":"crossref","first-page":"djw003","DOI":"10.1093\/jnci\/djw003","volume":"108","author":"WV Padula","year":"2016","unstructured":"Padula WV, Larson RA, Dusetzina SB, et al. Cost-effectiveness of tyrosine kinase inhibitor treatment strategies for chronic myeloid leukemia in chronic phase after generic entry of imatinib in the United States. JNCI J Natl Cancer Inst. 2016;108(7):djw003.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"587_CR9","volume-title":"China Guidelines for pharmacoeconomic Evaluations and Manual (2015 edition) [M]","author":"Guo-en Liu","year":"2015","unstructured":"Liu Guo-en. China Guidelines for pharmacoeconomic Evaluations and Manual (2015 edition) [M]. Beijing: Science Press Co. Ltd; 2015."},{"key":"587_CR10","unstructured":"List of Chinese administrative divisions by GDP per capita. \n                        http:\/\/en.wikipedia.org\/wiki\/List_of_Chinese_administrative_divisions_by_GDP_per_capita\n                        \n                    . Accessed 28 October 2011."},{"issue":"5","key":"587_CR11","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1111\/j.1524-4733.2004.75003.x","volume":"7","author":"HG Eichler","year":"2004","unstructured":"Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7(5):518\u201328.","journal-title":"Value Health"},{"issue":"3","key":"587_CR12","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O","volume":"9","author":"CJ Murray","year":"2000","unstructured":"Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235\u201351.","journal-title":"Health Econ"},{"issue":"1","key":"587_CR13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00277-008-0548-y","volume":"88","author":"Y Qin","year":"2009","unstructured":"Qin Y, Jiang B, Jiang Q, et al. Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-up. Ann Hematol. 2009;88(1):37\u201341.","journal-title":"Ann Hematol"},{"issue":"2","key":"587_CR14","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s11684-012-0202-x","volume":"6","author":"H He","year":"2012","unstructured":"He H, Shen Y, Zhu Y, et al. Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era. Front Med. 2012;6(2):204\u201311.","journal-title":"Front Med"},{"issue":"2","key":"587_CR15","first-page":"93","volume":"4","author":"L Zhou","year":"2013","unstructured":"Zhou L, Wang JX, Huang XJ, et al. Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnose chronic myeloid leukemia. Chin J Hematol. 2013;4(2):93\u20137.","journal-title":"Chin J Hematol"},{"issue":"9","key":"587_CR16","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.3109\/10428194.2013.866663","volume":"55","author":"CT Chuah","year":"2014","unstructured":"Chuah CT, Nakamae H, Shen ZX, et al. Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phase. Leuk Lymphoma. 2014;55(9):2093\u2013100.","journal-title":"Leuk Lymphoma"},{"issue":"18","key":"587_CR17","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","volume":"125","author":"J Wang","year":"2015","unstructured":"Wang J, Shen ZX, Saglio G, et al. Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood. 2015;125(18):2771\u20138.","journal-title":"Blood"},{"issue":"11","key":"587_CR18","first-page":"889","volume":"33","author":"XJ Huang","year":"2012","unstructured":"Huang XJ, Hu JD, Li JY, et al. Study on efficiency and safety of dasatinib in Chinese patients with chronic myelogenous leukemia who are resistant or intolerant to imatinib. Chin J Hematol. 2012;33(11):889\u201395.","journal-title":"Chin J Hematol"},{"issue":"3","key":"587_CR19","first-page":"581","volume":"21","author":"Y Zhu","year":"2013","unstructured":"Zhu Y, Pan LQ, Qian SX, et al. Efficacy of dasatinib in treatment of imatinib-resistant BCR\/ABL positive leukemia. J Exp Hematol. 2013;21(3):581\u20136.","journal-title":"J Exp Hematol"},{"issue":"7","key":"587_CR20","first-page":"1000","volume":"32","author":"YQ Wei","year":"2012","unstructured":"Wei YQ, Zhang X, Chen WW, et al. Long-term outcomes of nilotinib treatment for chronic myelogenous leukemia patients with imatinib resistance or intolerance. J South Med Univ. 2012;32(7):1000\u20133.","journal-title":"J South Med Univ"},{"issue":"6","key":"587_CR21","first-page":"1545","volume":"22","author":"LQ Pan","year":"2014","unstructured":"Pan LQ, Liu WX, Zhu Y, et al. Nilotinib treatment for patients with imatinib-resistant or intolerant chronic myeloid leukemia. J Exp Hematol. 2014;22(6):1545\u20139.","journal-title":"J Exp Hematol"},{"issue":"4","key":"587_CR22","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/00019053-199813040-00003","volume":"13","author":"A Briggs","year":"1998","unstructured":"Briggs A, Sculpher M. An introduction to Markov modeling for economic evaluation. Pharmacoeconomic. 1998;13(4):397\u2013409.","journal-title":"Pharmacoeconomic"},{"issue":"8","key":"587_CR23","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1002\/cncr.22569","volume":"109","author":"H Kantarjian","year":"2007","unstructured":"Kantarjian H, O\u2019Brien S, Talpaz M, et al. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure. Cancer. 2007;109(8):1556\u201360.","journal-title":"Cancer"},{"issue":"4","key":"587_CR24","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1600-0609.1996.tb01379.x","volume":"57","author":"F Cervantes","year":"1996","unstructured":"Cervantes F, L\u00f3pez-Guillermo A, Bosch F, et al. An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemia. Eur J Haematol. 1996;57(4):286\u201391.","journal-title":"Eur J Haematol"},{"key":"587_CR25","volume-title":"Decision making in health and medicine. Integrating evidence and values","author":"M Hunink","year":"2001","unstructured":"Hunink M, Glasziou P, Siegel J, et al. Decision making in health and medicine. Integrating evidence and values. Cambridge: Cambridge University Press; 2001."},{"key":"587_CR26","doi-asserted-by":"publisher","first-page":"982395","DOI":"10.1155\/2015\/982395","volume":"2015","author":"U Rochau","year":"2015","unstructured":"Rochau U, Kluibenschaedl M, Stenehjem D, et al. Effectiveness and cost-effectiveness of sequential treatment of patients with chronic myeloid leukemia in the United States: a decision analysis. Leuk Res Treatment. \u00a02015;2015:982395. doi: \n                        10.1155\/2015\/982395\n                        \n                    .","journal-title":"Leuk Res Treatment"},{"issue":"8","key":"587_CR27","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.3109\/10428194.2014.982635","volume":"56","author":"U Rochau","year":"2015","unstructured":"Rochau U, Sroczynski G, Wolf D, et al. Cost-effectiveness of the sequential application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia. Leuk Lymphoma. 2015;56(8):2315\u201325.","journal-title":"Leuk Lymphoma"},{"key":"587_CR28","doi-asserted-by":"crossref","first-page":"48","DOI":"10.7705\/biomedica.v34i1.1446","volume":"34","author":"M Romero","year":"2014","unstructured":"Romero M, Ch\u00e1vez D, De los R\u00edos M, et al. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia, 2012. Biom\u00e9dica. 2014;34:48\u201359.","journal-title":"Biom\u00e9dica"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-017-0587-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0587-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-017-0587-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T15:55:15Z","timestamp":1515599715000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-017-0587-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,13]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["587"],"URL":"https:\/\/doi.org\/10.1007\/s40261-017-0587-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,13]]}}}